Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Kyowa Kirin Seeks Additional Indication for Orkedia
April 25, 2019
- Poxel’s Novel Diabetes Med One Step Closer to World’s 1st Launch, Japan Chief Says Physicians’ Trust Holds Key
April 24, 2019
- Aducanumab Termination Was Wrenching Decision: Eisai CEO
April 24, 2019
- In Authorized Generic Spree, Daiichi Sankyo Espha Focuses More on “Popularization” than “Sales” When It Comes to Cancer AGs
April 24, 2019
- Teva Takeda to Shutter 2 Factories in Shiga
April 24, 2019
- Boehringer Seeks Additional Indication for Ofev
April 23, 2019
- Nippon Kayaku Grabs Japan Rights to Lilly’s Soon-to-Launch Portrazza
April 23, 2019
- Banned Doping Substance Contamination on API Production Line: Sawai Report
April 23, 2019
- MSD Japan Chief Flags Re-Pricing for Keytruda, Says It’s “Heading into That Range”
April 22, 2019
- SanBio Vows to Create In-House Marketing System in Japan by 2020, Eyes Global Leader by 2025: President
April 22, 2019
- Sumitomo Dainippon Cuts Sales Outlook for FY2018, Ups Profit Forecast
April 22, 2019
- Novartis to Begin Kymriah Treatment at 2-3 Japan Sites, Looks at Gradual Expansion
April 19, 2019
- Boehringer to Remain Major Employer in Japan with As-Needed Staffer Placement
April 19, 2019
- Chugai-Originated Eczema Drug Hits Primary Goal in Japan PIII: Maruho
April 19, 2019
- Pfizer Japan Mulls Over Alternative Manufacturing Route Following Suspension of Methotrexate Production in Germany
April 19, 2019
- SanBio Unveils Positive PII Data for SB623 in Traumatic Brain Injury
April 18, 2019
- Sanofi Pushing Drugs’ Added Values to Secure Patient Access amid Rising Awareness for Economic Efficiency
April 18, 2019
- Bayer, Hokkaido Pref. Join Forces to Tackle Life Style Diseases
April 18, 2019
- Japan Pharma Market Grew 87.1% in 30 Years of Heisei Era: IQVIA
April 18, 2019
- With Ozempic Listing in Limbo, Novo Japan Chief Says Single-Dose Device Launch Unlikely This Year
April 17, 2019
ページ
The number of newly listed generic drugs in Japan has fallen sharply over the past decade, reflecting structural changes in…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…